Patricia Kleinpeter, et al.OncoImmunology, October 2016 – Download the articlePublication
Catégorie : -other-fr
Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities
Johann Foloppe, et al.10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada – 1-4 October 2016Download the poster herePoster Presentation Collaboration between Transgene – HTS facility IGBMC, Illkirch – France IREBS, Illkirch, France – ICube, Strasbourg, France
Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene
Marine Ricordel, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor
Anita Spindler, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al.XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016Download the poster herePoster Presentation
A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Ghassan K. Abou-Alfa, et al. ASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois Download the poster here Poster Presentation
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
Jean Baptiste Marchand, et al.XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016Download the poster herePoster Presentation
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition
Jean Baptiste Marchand, et al. AACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana Download the poster here Poster Presentation
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Elisabeth Quoix, et al. The Lancet Oncology, December 2015, 17: 212–23 – Download the article Publication
A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates
Stephane Leung-Theung-Long, et al PLOS One, November 24, 2015 DOI: 10.1371/journal.pone.0143552 – Download the article Publication